Association of PRKAA1 gene polymorphisms with chronic hepatitis B virus infection in Chinese Han population

ABSTRACT

Objective:

Studies have indicated that AMPK play critical roles in the regulation of innate immunity and inflammatory responses. However, the role of the polymorphisms of PRKAA1 gene in immune-response to infectious organisms remains unknown. To evaluate the potential role of PRKAA1/AMPKα1 in the immune-response to HBV, we conducted this case-control study.

Methods:

We recruited 276 patients (145 men and 131 women; average age, 51.6 years) with chronic HBV infection (CHB) and 303 healthy controls (166 men and 137 women; average age, 54.2 years). All the subjects were unrelated individuals of Chinese Han Population. Three SNPs of PRKAA1gene were tested.

Results:

Rs1002424 polymorphism showed significant difference in the allele frequencies, but no difference in the genotype frequencies (allele: p = 0.039411, OR95%CI = 0.783479 [0.621067-0.988362]; genotype: p = 0.104758); rs13361707 polymorphism showed significance in allele analysis, but not in genotype analysis (allele: p = 0.034749, OR95%CI = 1.284303 [1.017958-1.620335]; genotype: p = 0.098027); rs3792822 polymorphism was demonstrated to have significant differences in both genotype and allele frequencies between cases and controls (allele: p = 0.029286, OR95%CI= 0.741519 [0.566439-0.970716]; genotype: p = 0.034560). The haplotype results showed that CTG and TCA in the rs13361707-rs1002424-rs3792822 block were significantly associated with the happening of HBV (CTG: p = 0.036854, OR95%CI = 1.281 [1.015-1.617]; p = 0.030841, OR95%CI = 0.743 [0.568-0.973]).

Conclusion:

These findings suggest that PRKAA1 polymorphisms may contribute to the susceptibility of chronic HBV infection in Chinese Han origin.

Keywords:
HBV; PRKAA1 gene; SNP; Association study

Introduction

Adenosine-monophosphate-activated protein kinase (AMPK) is highly conserved hetero-trimeric serine/threonine protein kinase consists of a catalytic subunit (α1 or α2) and two regulatory β (β1-2) and γ subunits (γ1-3).^1,2 It is ubiquitously expressed and served as a master sensor of cellular energy homeostasis at the cellular and even whole-body level. AMPK is activated by the increase of AMP/ATP ratio from environmental or nutritional stress factors including oxidants, hypoxia and nutrient deprivation,^3,4 then the activated kinase phosphorylates and regulates a variety of downstream molecules that maintains the balance between the consumption and generation of cellular energy.^5,6 Disruption of this balance results a number of diseases such as diabetes, obesity, cardiovascular dysfunction, inflammation and some malignant diseases.^7-9 In the last several years, accelerating evidence have indicated that AMPK plays critical roles in the regulation of innate immunity and inflammatory responses. Galic et al. reported that target deletion of AMPK β1 in mice enhanced adipose tissue macrophage inflammation and liver insulin resistance.¹⁰ While some other researchers demonstrated that AMPK-α1 is essential in mediating TLR4 or TNF-α triggered inflammatory signals as an activating kinase of TAK1.^11,12 AMPK-α1 is encoded by PRKAA1 gene which is located on chromosome 5p12.1 and constitutes a 39 kb region. Studies have indicated that nucleotide polymorphisms in PRKAA1 gene was significant associated with the risk of gastric, colon and rectal cancer.^13-16 However, the role of PRKAA1 gene in the immune-response to infectious organisms remains unknown.

Hepatitis B is one of the most common infectious diseases caused by the hepatitis B virus (HBV) which attacks the liver. Chronic hepatitis B virus infection (CHB) may lead to liver fibrosis and cirrhosis, and dramatically increase the incidence of hepatocellular carcinoma (HCC). The susceptibility and progression of this disease are known to be influenced by viral load, virus genotype, environmental factors, host immune responses and host genetic factors.^17,18 Considering the importance of PRKAA1 in the inflammatory signaling cascade, we conducted this case-control study to investigate the association between PRKAA1 and the susceptibility of chronic HBV infection in Chinese Han population.

Materials and methods

Study subjects

In this study, we recruited 276 patients (145 men and 131 women; average age, 51.6 years) with chronic HBV infection and 303 healthy controls (166 men and 137 women; average age, 54.2 years) from Shaanxi Province People's Hospital between Jan 2012 and Dec 2014. All the subjects were unrelated individuals of Chinese Han Population. The patients were diagnosed based on serological positivity for HBsAg, HBeAg or anti-HBe and anti-HBc for at least 6 months, and persistent abnormality of ALT (alanine aminotransferase) and AST (aspartate aminotransferase). All the patients were in the active hepatitis stage without evidence of liver cirrhosis and HCC. Patients with other diseases were excluded from this study. Healthy controls were randomly selected from healthy persons under routine health screening at the same hospital during the same time period. They were confirmed to be negative for HBsAg and HBeAg, without clinical evidence of hepatic disease, cancer and other disease. The main characteristics of the subjects are listed in the supplementary Table S1. Written informed consent was obtained from each participant of study. The study protocol conformed to the 1975 Declaration of Helsinki and was approved by the Research Ethics Committee of Shaanxi Province People's Hospital.

Genotyping of PRKAA1 gene polymorphisms

Genomic DNA was isolated from EDTA peripheral blood using the DNA Extraction Kit (Tiangen Biotech Co., Ltd., Beijing, China) following the manufacturer's instructions. All DNA samples were amplified for rs13361707, rs1002424 and rs3792822 by PCR (polymerase chain reaction) using TaKaRa PCR Amplification Kit (Takara Bio Inc.). The primers were designed using primer 5.0 software (Molecular Biology Insights) according to the sequence from NCBI. The primers for rs13361707 primers were: Forward: 5′-ACGTGTTAAGGAAATAGC-3′, and Reverse: 5′-AACTGTGTGTATAGTGCAGG-3′. The primers for rs1002424 were: Forward: 5′-AGTTTGGAAGTTATCAGATC-3′, and Reverse: 5′-ACAGGTGTGAGCCACAGCAC-3′. The primers for rs3792822 were: Forward: 5′-ACTAGCATCAAAATGTCAGC-3′, and Reverse: 5′-GACTAGCAAGGCCTAGATCT-3′. The PCR products were then sequenced and analyzed by ABI 3700 DNA automated sequencer (Applied Biosystems) according to the standard protocol.

Statistical analysis

Data management and statistical analyses were conducted by STATA software 11.0 version for Windows (StataCorp LP, College Station, TX, USA). Hardy-Weinberg equilibrium was tested using the χ ² test. Between-group variables were compared by unpaired Student's t-test or Mann-Whitney U test where appropriate, and genotype/allele frequencies were compared by χ ² test. The linkage disequilibrium and haplotype construction were performed from the observed genotypes using SHEsis method (http://www.nhgg.org/analysis), and odds ratios (OR) with 95% confidence interval (CI) were calculated. A two-tailed p < 0.05 was accepted as statistically significant.

Results

Single-point association analysis

There were no deviations from Hardy-Weinberg equilibrium for all studied polymorphisms in cases and controls (p > 0.05). Totally, three SNPs of PRKAA1gene were tested. Rs1002424 polymorphism showed difference in the allele frequencies (p = 0.039411, OR95%CI = 0.783479 [0.621067-0.988362]) but no differences in the genotype frequencies (p = 0.104758); Rs13361707 polymorphism showed significance in allele analysis (p = 0.034749, OR95%CI = 1.284303 [1.017958-1.620335]), but not in genotype analysis (p = 0.098027); rs3792822 polymorphism was demonstrated to have significant differences in both genotype and allele frequencies between cases and controls (allele: p = 0.029286, OR95%CI = 0.741519 [0.566439-0.970716]; genotype: p = 0.034560) (Table 1).

Table 1
Distribution of genotype and allele frequencies of three SNPs in the PRKAA1 in HBV patients and healthy controls.

SNP	HBV patients	Healthy controls	OR	95%CI	p Value
	(n = 276)	(n = 303)
rs13361707
Allele(freq)			1.284303	1.017958–1.620335	0.034749
C	269 (0.491)	259 (0.429)
T	279 (0.509)	345 (0.571)
Genotype(freq)					0.098027
CC	71 (0.259)	57 (0.189)
CT	127 (0.464)	145 (0.480)
TT	76 (0.277)	100 (0.331)
HWE	0.228904	0.729947
rs1002424
Allele(freq)			0.783479	0.621067–0.988362	0.039411
C	278(0.507)	343 (0.568)
T	270(0.493)	261 (0.432)
Genotype(freq)					0.104758
CC	76 (0.277)	99 (0.328)
CT	126 (0.460)	145 (0.480)
TT	72 (0.263)	58 (0.192)
HWE	0.184879	0.706059
rs3792822
Allele(freq)			0.741519	0.566439–0.970716	0.029286
A	121 (0.221)	167 (0.276)
G	427 (0.779)	437 (0.724)
Genotype(freq)					0.034560
AA	14 (0.051)	17 (0.056)
AG	93 (0.339)	133 (0.440)
GG	167 (0.609)	152 (0.503)
HWE	0.821795	0.079962

• Bold numbers represent P-values (P<0.05).

Haplotype analysis

The standardized measure of linkage disequilibrium (LD), denoted as ‘D′’ was estimated at all possible pairs of SNP loci. LD for each pair of SNPs in cases and controls is presented in Table 2. The D′-value or r ²-value showed strong linkage patterns were observed between rs13361707 and rs1002424 in all samples (D′ = 0.99), as well as among rs1002424 and rs3792822 (D′ = 0.99), and between rs13361707 and rs3792822 (D′ = 0.99) (Fig. 1).

Table 2
Estimation of linkage disequilibrium between the 3 SNPs.

	rs13361707	rs1002424	rs3792822
rs13361707	–	0.996	1.000
rs1002424	0.983	–	1.000
rs3792822	0.282	0.285	–

• SNP, single nucleotide polymorphism.For each pair of SNPs, D′ values are shown above and r ² values below the diagonal, D’ or r ² > 0.9 are shown in boldface.

Fig. 1
LD patterns of SNPs rs13361707, rs1002424 and rs3792822. The linkage patterns between the 3 studied polymorphisms in all samples. The numbers in diamond represent the 100× D′ in the form of standard color scheme. The upper bar denotes the relative distance among the studied polymorphisms.

To facilitate identification of combinational effects of these three polymorphisms on the risk of chronic HBV infection, we employed haplotype analysis to study the frequency of the combination of multiple genetic variants. The results showed that CTG and TCA in the rs13361707-rs1002424-rs3792822 block were significantly associated with the development of chronic HBV infection (CTG: p = 0.036854, OR95%CI = 1.281 [1.015-1.617]; p = 0.030841, OR95%CI = 0.743 [0.568-0.973]) (Table 3).

Table 3
Haplotype analysis: rs13361707, rs1002424, rs3792822.

	Case (freq)	Control (freq)	Pearson's p	χ 2	Odds ratio [95%CI]
C T A	0.01 (0.000)	0.01 (0.000)	–	–	–
C T G*	267.99 (0.489)	258.99 (0.429)	0.036854	4.358	1.281 [1.015–1.617]
T C A*	120.99 (0.221)	166.98 (0.276)	0.030841	4.663	0.743 [0.568–0.973]
T C G*	156.00 (0.285)	176.02 (0.291)	0.818643	0.053	0.971 [0.752–1.253]
T T A	0.00 (0.000)	0.01 (0.000)	–	–	–
T T G	2.00 (0.004)	1.99 (0.003)	–	–	–
C C G	1.00 (0.002)	0.00 (0.000)	–	–	–

• (All those frequency <0.03 will be ignored in analysis.)Global χ ² is 5.885321 while df = 2.Pearson's p value is 0.052725.Bold numbers represent P-values (P<0.05).

Discussion

Chronic hepatitis B virus infection (CHB) is one of the most common infectious disease which leads to a huge economic problem on health care systems worldwide. According to the data from WHO, about 240 million people are chronically infected with hepatitis B and more than 780,000 people die from hepatitis B related diseases including cirrhosis and liver cancer each year (http://www.who.int/mediacentre/factsheets/fs204/en/). Thus it is important to clarify the mechanism of chronic HBV infection. Recent studies have shown that chronic hepatitis B virus infection is resulted from the interplay between the virus, host immune system and environmental factors.^19,20 Among of them, host genetic backgrounds may be critical for the susceptibility and various outcomes of this disease.^21,22 A number of genes have been identified to be associated with chronic hepatitis B virus infection by genome-wide association studies and case-control studies in the last several years.^23-25 More knowledge on the understanding of candidate genetic factors may provide more clues to the prevention and therapy of this disease.

It has been well documented that AMPK is an important regulator of energy-sensing and signaling cascade in mammalian cells.²⁶ As a heterotrimeric complex serine/threonine protein kinase, AMPK can regulate a variety of other physiological functions such as the regulation of cell proliferation and polarity, tumorigenesis, autophagy and innate immune responses.²⁷ However, the signaling properties are diverse depending on the different combination of subunit isoforms of AMPK in various cells.²⁸ Some studies indicated that AMPK may restrict HBV replication through promotion of autophagic degradation, but the underlying mechanism remains to be elucidated.²⁹ The α1 catalytic subunit of AMPK encoded by PRKAA1 gene, is mainly expressed in lymphocytes and macrophages. AMPKα1 has been demonstrated to play a pivotal role in inducing pro-inflammatory signals through the activation of TAK1 and NF-κB,³⁰ but its role in chronic HBV infection remains unclear. So, this current study might be the first attempt to assess the association between polymorphisms in PRAA1 gene and chronic HBV infection. The results showed that all the three polymorphisms we tested were associated with the susceptibility of chronic HBV infection (rs3792822 in both the allele- and genotype-analyses; rs13361707 and rs1002424 in allele-analyses). Based on the value of D′, the following haplotype-analyses were done and the results showed that, in the block of ‘rs13361707-rs1002424-rs3792822′, C T G and T C A were associated with chronic hepatitis B virus infection, suggesting that AMPKα1 may play some critical roles in the regulation of the initial defense against hepatitis B virus.

Taken together, the results of our study indicated that PRKAA1 gene is associated with the development of chronic HBV infection in Chinse Han Population. Although replications with larger sample size and functional studies to further clarify the role that PRKAA1/AMPKα1 are needed, the current study gave some clues which is useful in better understanding the intrinsic relationship between PRKAA1/AMPKα1 and the pathogenesis of chronic HBV infection.

Acknowledgments

This work was supported by grants from National High Technology Research and Development Program 863 (2014AA022304); Shaanxi Province Natural Science Foundation Research Project (2014JM2-8201).

References

• ¹
  Stapleton D, Woollatt E, Mitchelhill KI, et al. AMP-activated protein kinase isoenzyme family: subunit structure and chromosomal location. FEBS Lett. 1997;409:452-6.
• ²
  Carling D, Thornton C, Woods A, Sanders MJ. AMP-activated protein kinase: new regulation, new roles. Biochem J. 2012;445:11-27.
• ³
  Xiao B, Heath R, Saiu P, et al. Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature. 2007;449:496-500.
• ⁴
  Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007;8:774-85.
• ⁵
  Hardie DG, Pan DA. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans. 2002;30:1064-70.
• ⁶
  Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132-41.
• ⁷
  Kim EK, Park JM, Lim S, et al. Activation of AMP-activated protein kinase is essential for lysophosphatidic acid-induced cell migration in ovarian cancer cells. J Biol Chem. 2011;286:24036-45.
• ⁸
  Krishan S, Richardson DR, Sahni S. Gene of the month. AMP kinase (PRKAA1). J Clin Pathol. 2014;67:758-63.
• ⁹
  Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9:563-75.
• ¹⁰
  Galic S, Fullerton MD, Schertzer JD, et al. Hematopoietic AMPK beta1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J Clin Invest. 2011;121:4903-15.
• ¹¹
  Yang Z, Kahn BB, Shi H, Xue BZ. Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem. 2010;285:19051-9.
• ¹²
  Kim SY, Jeong S, Jung E, et al. AMP-activated protein kinase-alpha1 as an activating kinase of TGF-beta-activated kinase 1 has a key role in inflammatory signals. Cell Death Dis. 2012;3:e357.
• ¹³
  Mocellin S, Verdi D, Pooley KA, Nitti D. Genetic variation and gastric cancer risk: a field synopsis and meta-analysis. Gut. 2015;64:1209-19.
• ¹⁴
  Lee SJ, Kang BW, Chae YS, et al. Genetic variations in STK11, PRKAA1, and TSC1 associated with prognosis for patients with colorectal cancer. Annals Surg Oncol. 2014;21(Suppl. 4):S634-9.
• ¹⁵
  Kim YD, Yim DH, Eom SY, et al. Risk of gastric cancer is associated with PRKAA1 gene polymorphisms in Koreans. World J Gastroenterol. 2014;20:8592-8.
• ¹⁶
  Song HR, Kim HN, Kweon SS, et al. Genetic variations in the PRKAA1 and ZBTB20 genes and gastric cancer susceptibility in a Korean population. Mol Carcinogen. 2013;52(Suppl. 1):E155-60.
• ¹⁷
  Yu R, Fan R, Hou J. Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China. Frontiers Med. 2014;8:135-44.
• ¹⁸
  McMahon BJ. Chronic hepatitis B virus infection. Med Clin North Am. 2014;98:39-54.
• ¹⁹
  Busch K, Thimme R. Natural history of chronic hepatitis B virus infection. Med Microbiol Immunol. 2015;204:5-10.
• ²⁰
  Hua W, Zhang G, Guo S, Li W, Sun L, Xiang G. Microarray-based genotyping and detection of drug-resistant HBV mutations from 620 Chinese patients with chronic HBV infection. Braz J Infect Dis. 2015;19:291-5.
• ²¹
  Al-Qahtani A, Al-Anazi M, Viswan NA, et al. Role of single nucleotide polymorphisms of KIF1B gene in HBV-associated viral hepatitis. PLoS ONE. 2012;7:e45128.
• ²²
  Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int: Off J Int Assoc Study Liver. 2009;29(Suppl. 1):100-7.
• ²³
  Al-Qahtani A, Khalak HG, Alkuraya FS, et al. Genome-wide association study of chronic hepatitis B virus infection reveals a novel candidate risk allele on 11q22.3. J Med Genet. 2013;50:725-32.
• ²⁴
  Liang LB, Chen LL, Chen EQ, Liao J, Tang H. Genotypic resistance profiles in Chinese patients with chronic hepatitis B virus infection and the efficacy of nucleoside analog rescue therapy. Therapeut Clin Risk Manage. 2015;11:417-23.
• ²⁵
  Tuncbilek S. Relationship between cytokine gene polymorphisms and chronic hepatitis B virus infection. World J Gastroenterol. 2014;20:6226-35.
• ²⁶
  Carling D, Mayer FV, Sanders MJ, Gamblin SJ. AMP-activated protein kinase: nature's energy sensor. Nat Chem Biol. 2011;7:512-8.
• ²⁷
  Steinberg GR, Schertzer JD. AMPK promotes macrophage fatty acid oxidative metabolism to mitigate inflammation: implications for diabetes and cardiovascular disease. Immunol Cell Biol. 2014;92:340-5.
• ²⁸
  Voss U, Ekblad E. Lipopolysaccharide-induced loss of cultured rat myenteric neurons - role of AMP-activated protein kinase. PLoS ONE. 2014;9:e114044.
• ²⁹
  Douglas DN, Pu CH, Lewis JT, et al. Oxidative stress attenuates lipid synthesis and increases mitochondrial fatty acid oxidation in hepatoma cells infected with hepatitis C virus. J Biol Chem. 2016;291:1974-90.
• ³⁰
  Kim SY, Jeong S, Jung E, et al. AMP-activated protein kinase-alpha1 as an activating kinase of TGF-beta-activated kinase 1 has a key role in inflammatory signals. Cell Death Disease. 2012;3:e357.

Publication Dates

• Publication in this collection
  Nov-Dec 2016

History

• Received
  6 May 2016
• Accepted
  2 Aug 2016